Sigilon Therapeutics, Inc.
SGTX evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- mps-1 program (Preclinical)
What it means
What to watch
Prepared research question
What matters most for SGTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
mps-1 program (Preclinical)
Next Catalyst
—
Tracking 5 pipeline candidates · 2 clinical trials for Sigilon Therapeutics, Inc..
Run Sigilon Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sigilon Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1/Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Sigilon Therapeutics, Inc.'s lead drug candidate?
Sigilon Therapeutics, Inc.'s most advanced tracked candidate is mps-1 program (Preclinical) for mucopolysaccharidosis type 1.
Who is the CEO of Sigilon Therapeutics, Inc.?
Rogerio Vivaldi Coelho, M.D. is the chief executive officer of Sigilon Therapeutics, Inc. (SGTX).
What therapeutic areas does Sigilon Therapeutics, Inc. focus on?
Sigilon Therapeutics, Inc. develops therapies across Rare Disease, Metabolic, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.